Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Johnson and Johnson
Boehringer Ingelheim

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 8,080,248

  Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,080,248
Title:Method of treating rheumatoid arthritis with an IL-6R antibody
Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
Inventor(s): Radin; Allen (New York, NY), Stevens; Sean (San Diego, CA), Huang; Tammy T. (Goldens Bridge, NY), Martin; Joel H. (Putnam Valley, NY), Fairhurst; Jeanette L. (White Plains, NY), Rafique; Ashique (Yonkers, NY), Smith; Eric (New York, NY), Pobursky; Kevin J. (Beacon, NY), Papadopoulos; Nicholas J. (LaGrangeville, NY), Fandl; James P. (LaGrangeville, NY), Chen; Gang (Yorktown Heights, NY), Karow; Margaret (Camarillo, CA)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:12/780,006
Patent Claims:see list of patent claims

Details for Patent 8,080,248

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2026-06-02 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Try a Free Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2026-06-02 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Try a Free Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2026-06-02 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.